Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1931-1940 Newer>

BusinessWeek April 25, 2005 Gene G. Marcial	Affymetrix: A Lab Boost The GeneChip can reduce the risk of adverse reactions to drugs by checking the recipient's DNA against the drug's profile. Some people are optimistic about the company's stock.
The Motley Fool April 14, 2005 Rich Duprey	Mentor the Winner on Implants An FDA panel gives Mentor the right to market breast implants after denying Inamed's application. On the news, Inamed's stock fell by more than 3%, and then nearly 7% in early morning trading.
The Motley Fool April 14, 2005 Brian Gorman	Novartis Moves on Multiple Fronts Even with its investment in a potential blockbuster, Novartis remains remarkably diversified. Investors can rest assured, though, that the company's strategy won't leave it as vulnerable as other outfits.
The Motley Fool April 12, 2005 Charly Travers	Where Did the Earnings Go? Expensing stock options will not be kind to some prominent biotechs.
The Motley Fool April 12, 2005 Brian Gorman	Genentech's Cancer Quest The company's achievements in lung cancer further strengthen its reputation as a cancer fighter. Would-be investors are best served by waiting patiently.
The Motley Fool April 8, 2005 Stephen D. Simpson	Abbott Hopes to Maxx Out Abbott announced FDA approval to begin a pivotal trial for its drug-eluting stent. Will this be too little too late for shareholders, or a true dark horse?
The Motley Fool April 8, 2005 David Nierengarten	The Psoriasis Wars Continue Biogen-Idec hopes its new drug will conquer the lucrative psoriasis market. Investors should consider taking a second look at the company's prospects.
The Motley Fool April 8, 2005 Brian Gorman	Cubist in Neutral Cubist Pharmaceuticals' pipeline may be why investors are unimpressed.
The Motley Fool April 8, 2005 Stephen D. Simpson	Alkermes' Alcohol Alchemy A new formulation of an old drug could help alcoholics and make shareholders happy.
The Motley Fool April 8, 2005 Charly Travers	The FDA Hammers Pfizer Regulatory agency orders a billion dollar blockbuster off the market. Should investors care?
<Older 1931-1940 Newer> Return to current articles.